First COVID-19 vaccine trial begins in the United States
On March 16, 2020, the United States of America began the first human trial evaluating COVID-19 vaccine. The US National Institute of Health will enroll 45 healthy adult volunteers between age 18 and 55 for a period of 6 weeks in order to test the vaccine.
A healthy volunteer from Seattle, Kaiser Permante of Washington was injected with the vaccine. The vaccine was developed by a private firm called Moderna.
Under the vaccination of COVID-19, three different doses are to be tested. During the trial phase, it is to be studied if the vaccines are safe and whether they stimulate the immune system of humans to create antibodies to stop COVID-19.
The vaccine has been synthesized from a stretch of RNA embedded in a lipid nano particle. The Food and Drug Administration recently permitted to the trial tests of the vaccine.
Clinical Trials in India
Recently, the Indian Council of Medical Research announced that, it will take minimum of two years for India to develop a vaccine against Corona Virus. While India was able to isolate the virus strains, it is challenging for the country to develop a vaccine against the disease.
This is mainly because, the number of clinical trials in India is far less as compared to other countries. India contributes only 2.7% of global clinical trials. On the other hand, the US contributes 47%, followed by EU of 18%, Japan of 11%.
In order to improve the situation, India should take active part in platforms like ICTRP of the World Health Organization
ICTRP of WHO
The International Clinical Trials Registry Platform of WHO is a mission aimed to make sure a complete view of research is accessible to those who are involved in health care trials.
Category: International Current Affairs
|View All E-Books: Recent Release|